Talk:COVID-19 drug repurposing research

This is the talk page for discussing improvements to the COVID-19 drug repurposing research article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: 1, 2: 14 days

COVID-19 B‑class High‑importance

	COVID-19 portal This article is within the scope of WikiProject COVID-19, a project to coordinate efforts to improve all COVID-19-related articles. If you would like to help, you are invited to join and to participate in project discussions.COVID-19Wikipedia:WikiProject COVID-19Template:WikiProject COVID-19COVID-19 articles
B	This article has been rated as B-class on Wikipedia's content assessment scale.
High	This article has been rated as High-importance on the project's importance scale.

Medicine: Society / Pulmonology B‑class Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
B	This article has been rated as B-class on Wikipedia's content assessment scale.
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Society and Medicine task force (assessed as Mid-importance).
	This article is supported by the Pulmonology task force (assessed as Mid-importance).

Pharmacology B‑class Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
B	This article has been rated as B-class on Wikipedia's content assessment scale.
Mid	This article has been rated as Mid-importance on the project's importance scale.

Viruses B‑class Mid‑importance

	Viruses portal This article is within the scope of WikiProject Viruses, a collaborative effort to improve the coverage of viruses on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.VirusesWikipedia:WikiProject VirusesTemplate:WikiProject Virusesvirus articles
B	This article has been rated as B-class on Wikipedia's content assessment scale.
Mid	This article has been rated as Mid-importance on the project's importance scale.

Disaster management B‑class Mid‑importance

	This article is within the scope of WikiProject Disaster management, a collaborative effort to improve the coverage of Disaster management on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.Disaster managementWikipedia:WikiProject Disaster managementTemplate:WikiProject Disaster managementDisaster management articles
B	This article has been rated as B-class on Wikipedia's content assessment scale.
Mid	This article has been rated as Mid-importance on the project's importance scale.

International relations B‑class Mid‑importance

	This article is within the scope of WikiProject International relations, a collaborative effort to improve the coverage of International relations on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.International relationsWikipedia:WikiProject International relationsTemplate:WikiProject International relationsInternational relations articles
B	This article has been rated as B-class on Wikipedia's content assessment scale.
Mid	This article has been rated as Mid-importance on the project's importance scale.

WikiProject COVID-19 consensus

WikiProject COVID-19 aims to add to and build consensus for pages relating to COVID-19. They have so far discussed items listed below. Please discuss proposed improvements to them at the project talk page.

General

Superseded by TfD October 2020 and later practice - consult regular {{Current}} guidance.

Refrain from using Worldometer (worldometers.info) as a source due to common errors being observed as noted on the Case Count Task Force common errors page. (April 2020, April 2020)

For infoboxes on the main articles of countries, use Wuhan, Hubei, China for the origin parameter. (March 2020)

"Social distancing" is generally preferred over "physical distancing". (April 2020, May 2020)

Page title

COVID-19 (full caps) is preferable in the body of all articles, and in the title of all articles/category pages/etc.(RM April 2020, including the main article itself, RM March 2021).

SARS-CoV-2 (exact capitalisation and punctuation) is the common name of the virus and should be used for the main article's title, as well as in the body of all articles, and in the title of all other articles/category pages/etc. (June 2022, overturning April 2020)

Map

There is no consensus about which color schemes to use, but they should be consistent within articles as much as possible. There is agreement that there should be six levels of shading, plus gray for areas with no instances or no data. (May 2020)

There is no consensus about whether the legend, the date, and other elements should appear in the map image itself. (May 2020)

For map legends, ranges should use fixed round numbers (as opposed to updating dynamically). There is no consensus on what base population to use for per capita maps. (May 2020)

To ensure you are viewing the current list, you may wish to purge this page.

Daily pageviews of this article

A graph should have been displayed here but graphs are temporarily disabled. Until they are enabled again, visit the interactive graph at pageviews.wmcloud.org

This is the talk page for discussing improvements to the COVID-19 drug repurposing research article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: 1, 2: 14 days

The contentious topics procedure applies to this page. This page is related to COVID-19, broadly construed, which has been designated as a contentious topic.

Editors who repeatedly or seriously fail to adhere to the purpose of Wikipedia, any expected standards of behaviour, or any normal editorial process may be blocked or restricted by an administrator. Editors are advised to familiarise themselves with the contentious topics procedures before editing this page.

Extended-confirmed-protected edit request on 22 June 2021

This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request.

‹ The template Edit extended-protected is being considered for merging. ›

In 22, Jun 2021 philippines president Rodrigo Duterte publicly stated that ivermectin is "used for pigs"^[1]^[2]

Please update the article with this new information. Kreyren (talk) 21:06, 22 June 2021 (UTC)[reply]

Not done: it's not clear what changes you want to be made. Please mention the specific changes in a "change X to Y" format and provide a reliable source if appropriate. ScottishFinnishRadish (talk) 00:11, 23 June 2021 (UTC)[reply]

References

Extended-confirmed-protected edit request on 28 June 2021

This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request.

‹ The template Edit extended-protected is being considered for merging. ›

Propose adding to the ivermectin section: "Despite the lack of FDA approval for COVID-19 treatment, an increase in off-label ivermectin prescriptions occurred in the US^[1] following initial publications showing potential benefit. "During March 16, 2019–April 2, 2021, national estimates of ivermectin dispensed from outpatient retail pharmacies increased from an average of 3589 prescriptions per week at the pre-pandemic baseline to a peak of 39,102 prescriptions in the week ending on January 8, 2021 (989% relative percent increase)"^[2]

I think this would follow well after "Ivermectin is not approved by the U.S. Food and Drug Administration (FDA) for use in treating any viral illness and is not authorized for use to treat COVID-19 within the European Union" Caprilyc (talk) 13:39, 28 June 2021 (UTC)[reply]

References

^ Lind, Jennifer; Lovegrove, Maribeth; Geller, Andrew; Uyeki, Timothy; Datta, S Deblina; Budnitz, Daniel (18 June 2021). "Increase in Outpatient Ivermectin Dispensing in the US During the COVID-19 Pandemic: A Cross-Sectional Analysis". Journal of General Internal Medicine. doi:10.1007/s11606-021-06948-6.
^ Geller, Andrew; Lovegrove, Maribeth; Lind, Jennifer (11 Feb 2021). "Assessment of Outpatient Dispensing of Products Proposed for Treatment or Prevention of COVID-19 by US Retail Pharmacies During the Pandemic". JAMA Internal Medicine. 181 (6): 869–872. doi:10.1001/jamainternmed.2021.0299.

Not done The source for "showing potential benefit" is a letter, and doesn't support it in any case. More generall this is not relevant to the topic of "drug repurposing research". Maybe something respectful of WP:V could be due at COVID-19 misinformation. Alexbrn (talk) 13:58, 28 June 2021 (UTC)[reply]

I don't have edit access there and the talk page is locked as well but propose adding "Despite the lack of FDA approval for COVID-19 treatment, an increase in off-label ivermectin prescriptions occurred in the US^[1] following widespread media coverage of the drug. "During March 16, 2019–April 2, 2021, national estimates of ivermectin dispensed from outpatient retail pharmacies increased from an average of 3589 prescriptions per week at the pre-pandemic baseline to a peak of 39,102 prescriptions in the week ending on January 8, 2021 (989% relative percent increase)"^[2] Caprilyc (talk) 15:20, 28 June 2021 (UTC)[reply]

Caprilyc possibly also at Ivermectin and/or COVID-19 pandemic in the United States if it's notable. Alaexis_¿question? 14:43, 28 June 2021 (UTC)[reply]

Point taken. I did not mean to add it as an endorsement of efficacy, more as a statement on how even very preliminary scientific findings affected physician behavior in the field. Given that there is discussion of people taking horse dewormer perhaps that is also better moved to COVID-19 misinformation instead of this research section. Caprilyc (talk) 15:01, 28 June 2021 (UTC)[reply]

Not done: it's not clear what changes you want to be made. Please mention the specific changes in a "change X to Y" format and provide a reliable source if appropriate. Melmann 09:29, 30 June 2021 (UTC)[reply]

Extended-confirmed-protected edit request on 1 July 2021

This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request.

‹ The template Edit extended-protected is being considered for merging. ›

Concerning Ivermectin, it seems reasonable to include a statement, such as:

The National Institute of Health (NIH) is currently neutral in its stance on the efficacy of Ivermectin as a COVID-19 therapy: "There are insufficient data for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of ivermectin for the treatment of COVID-19. Results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide more specific, evidence-based guidance on the role of ivermectin in the treatment of COVID-19." "Some observational cohorts and clinical trials have evaluated the use of ivermectin for the prevention and treatment of COVID-19." See, https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ivermectin/ 2600:8802:330F:A00:895B:ADAD:F26F:315A (talk) 20:04, 1 July 2021 (UTC)[reply]

References

^ Lind, Jennifer; Lovegrove, Maribeth; Geller, Andrew; Uyeki, Timothy; Datta, S Deblina; Budnitz, Daniel (18 June 2021). "Increase in Outpatient Ivermectin Dispensing in the US During the COVID-19 Pandemic: A Cross-Sectional Analysis". Journal of General Internal Medicine. doi:10.1007/s11606-021-06948-6.
^ Geller, Andrew; Lovegrove, Maribeth; Lind, Jennifer (11 Feb 2021). "Assessment of Outpatient Dispensing of Products Proposed for Treatment or Prevention of COVID-19 by US Retail Pharmacies During the Pandemic". JAMA Internal Medicine. 181 (6): 869–872. doi:10.1001/jamainternmed.2021.0299.

Not done The position of the NIH is already included in the article. Alexbrn (talk) 20:11, 1 July 2021 (UTC)[reply]

Invermectin again. Claimed peer reviewed meta-analysis.

This any use? https://journals.lww.com/americantherapeutics/Fulltext/2021/06000/Review_of_the_Emerging_Evidence_Demonstrating_the.4.aspx

Regards all. Springnuts (talk) 06:49, 2 July 2021 (UTC)[reply]

No. It's been raised (in at least 3 sections) at Talk:Ivermectin. Alexbrn (talk) 06:57, 2 July 2021 (UTC)[reply]

Thank you. Springnuts (talk) 19:12, 3 July 2021 (UTC)[reply]

Extended-confirmed-protected edit request on 4 July 2021

It is requested that an edit be made to the extended-confirmed-protected article at COVID-19 drug repurposing research. (edit · history · last · links · protection log)

This template must be followed by a complete and specific description of the request, that is, specify what text should be removed and a verbatim copy of the text that should replace it. "Please change X" is not acceptable and will be rejected; the request must be of the form "please change X to Y".

The edit may be made by any extended confirmed user. Remember to change the |answered=no parameter to "yes" when the request has been accepted, rejected or on hold awaiting user input. This is so that inactive or completed requests don't needlessly fill up the edit requests category. You may also wish to use the {{EEp}} template in the response. To request that a page be protected or unprotected, make a protection request.

‹ The template Edit extended-protected is being considered for merging. ›

There is now peer reviewed evidence that Ivermectin does work for CoVid. https://journals.lww.com/americantherapeutics/Abstract/9000/Ivermectin_for_Prevention_and_Treatment_of.98040.aspx 108.243.106.82 (talk) 23:45, 4 July 2021 (UTC)[reply]

[1] ttps://www.youtube.com/watch?v=T6DCuND1RR0

[2] ttps://edition.cnn.com/2021/06/21/asia/philippines-duterte-covid-vaccine-jail-intl-hnk/index.html

[3] Lind, Jennifer; Lovegrove, Maribeth; Geller, Andrew; Uyeki, Timothy; Datta, S Deblina; Budnitz, Daniel (18 June 2021). "Increase in Outpatient Ivermectin Dispensing in the US During the COVID-19 Pandemic: A Cross-Sectional Analysis". Journal of General Internal Medicine. doi:10.1007/s11606-021-06948-6.

[4] Geller, Andrew; Lovegrove, Maribeth; Lind, Jennifer (11 Feb 2021). "Assessment of Outpatient Dispensing of Products Proposed for Treatment or Prevention of COVID-19 by US Retail Pharmacies During the Pandemic". JAMA Internal Medicine. 181 (6): 869–872. doi:10.1001/jamainternmed.2021.0299.

[5] Lind, Jennifer; Lovegrove, Maribeth; Geller, Andrew; Uyeki, Timothy; Datta, S Deblina; Budnitz, Daniel (18 June 2021). "Increase in Outpatient Ivermectin Dispensing in the US During the COVID-19 Pandemic: A Cross-Sectional Analysis". Journal of General Internal Medicine. doi:10.1007/s11606-021-06948-6.

[6] Geller, Andrew; Lovegrove, Maribeth; Lind, Jennifer (11 Feb 2021). "Assessment of Outpatient Dispensing of Products Proposed for Treatment or Prevention of COVID-19 by US Retail Pharmacies During the Pandemic". JAMA Internal Medicine. 181 (6): 869–872. doi:10.1001/jamainternmed.2021.0299.

[1]

[2]

[1]

[2]

[1]

[2]